MOVE Medacta Group

DGAP-News: Mid Stabilisation Notice - Medacta Group SA

DGAP-News: Credit Suisse Securities (Europe) Limited / Key word(s): Miscellaneous
Mid Stabilisation Notice - Medacta Group SA

17.04.2019 / 19:30
The issuer is solely responsible for the content of this announcement.


17/04/2019

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.


Medacta Group SA

Mid-stabilisation Period Announcement


Credit Suisse Securities (Europe) Limited (contact: Lloyd Adams; +44 (0) 207 888 6341) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities within the limitations of Article 126 of the Swiss Ordinance on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading (FMIO).


Securities

Issuer: Medacta Group SA
Guarantor (if any): N/A
Aggregate nominal amount: 855,000 Registered Shares
Description: Registered Shares
Stabilisation Manager(s): Credit Suisse Securities (Europe) Limited

(Acting on behalf of Credit Suisse AG)
 




Stabilisation transaction[s]

Date Price Limit (CHF) Units Bought
11/04/2019 96.00 50,000
11/04/2019 95.60 50,000
11/04/2019 95.45 50,000
12/04/2019 95.20 32,500
15/04/2019 95.15 15,500
16/04/2019 95.15 4,797
16/04/2019 95.27 10,000
17/04/2019 95.15 30,000
17/04/2019 95.00 30,000
17/04/2019 94.50 30,000
17/04/2019 94.00 30,000
17/04/2019 93.50 13,057
 

 

Stabilisation trading venue SIX - SWISS EXCHANGE
 



This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit .



17.04.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: Credit Suisse Securities (Europe) Limited
Taunustor 1
60310 Frankfurt
Germany
Phone:
E-mail:
Internet: -suisse.com
ISIN: CH0468525222
Listed: Regulated Market in Frankfurt (Prime Standard)
EQS News ID: 801447

 
End of News DGAP News Service

801447  17.04.2019 

fncls.ssp?fn=show_t_gif&application_id=801447&application_name=news&site_id=research_pool
EN
17/04/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medacta Group

Maria Vara ... (+3)
  • Maria Vara
  • Oscar Haffen Lamm
  • Valliant Campagne

Suspension of coverage

From 2nd of June we are suspending coverage of companies below due to a reallocation of resources. Our prior estimates should no longer be used as an indicator for the company moving forward.INNATE PHARMAINVENTIVAMEDACTAMEDARTISONWARD MEDICALVALNEVA

Maria Vara
  • Maria Vara

Medacta: model update - Buy rating reiterated, unchanged CHF160 PT

We update our model following the publication of the company's annual report. No changes have been applied to our revenue forecast as FY 2024 results and 2025 guidance are aligned with our estimates. On the P&L, we have softened our S&M expenses expectation as these stood more towards 35.5%

 PRESS RELEASE

Medacta publishes 2025 Annual General Meeting invitation

Medacta Group SA / Key word(s): AGMEGM Medacta publishes 2025 Annual General Meeting invitation 08.04.2025 / 10:00 CET/CEST Press Release                     Medacta publishes 2025 Annual General Meeting invitation  CASTEL SAN PIETRO, 8 April 2025 – Medacta Group SA (“Medacta”, SIX:MOVE) published today the invitation to the Annual General Meeting (“AGM”) which will take place on Wednesday, 7 May 2025 at 11.00 a.m. at the Group premises in Via alla Rossa 6, Rancate, Switzerland. Shareholders can register to attend the Annual General Meeting in person but will also be abl...

Maria Vara
  • Maria Vara

Medacta: Exceptional FY2024 to fuel sustainable growth, adj. EBITDA hi...

Medacta reported preliminary unaudited FY 2024 revenue in early February; hence, the EUR590.6m figure was not a surprise. Nonetheless, we may highlight again that all four business lines delivered above the market growth with double-digit cc gains with a broad base geographical contribution. Gross

Maria Vara
  • Maria Vara

Medacta: expanding SportsMed footprint with Parcus Medical acquisition

Medacta expands its SportMeds footprint by acquiring Parcus Medical, a distinguished player with a diverse product family in sports medicine spanning the shoulder, knee, hip, and foot & ankle, with FY2024 unaudited revenues of USD16m. The acquisition not only expands Medacta's offering but also

ResearchPool Subscriptions

Get the most out of your insights

Get in touch